Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter, Entecavir-based, Phase III Clinical Trial of Hydronidone Capsule in the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B

NCT05115942 is registered in ClinicalTrials.gov with Beijing Continent Pharmaceutical Co, Ltd. as lead sponsor.

NCT NCT05115942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05115942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Entecavir-based, Phase III Clinical Trial of Hydronidone Capsule in the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B
Lead sponsor
Beijing Continent Pharmaceutical Co, Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 30, 2021
Completion date
October 22, 2024
Enrollment
248 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

liver fibrosis